Report: Amarin's Promising Results Call Attention to Neptune Technologies & Bioressources
19 Abril 2011 - 9:08AM
Marketwired
Monday's promising results from Amarin's new cholesterol drug led
to speculation the company could be a takeover target, but Neptune
Technologies & Bioressources Inc. ("Neptune") (NASDAQ: NEPT)
(TSX-V: NTB) is aiming for cholesterol/hyperlipidemia's ultimate
prize.
Neptune's Omega-3 nutraceutical, Neptune Krill Oil (NKO) has
shown efficacy in human trials in three key areas:
1) Triglyceride and good-and-bad-cholesterol management
(hyperlipidemia)
2) Inflammation/Arthritis
3) Adult ADHD. A 120-patient human trial showed that NKO reduced
LDL (bad cholesterol) by 33.9%, reduced triglycerides by 11.5%, and
increased HDL (good cholesterol) by 43.3%. Anyone who knows the
cholesterol/hyperlipidemia space knows that finding a single
substance that has these effects (with NO toxicity) is like finding
the Holy Grail -- and NKO has no toxicity (it has GRAS status from
the FDA).
Recently named a finalist for the 2011 Nutraceutical &
Business Technology (NBT) Awards in the category of Outstanding
Application in Health Management, Neptune has a wide variety of
patented substances and processes in 3 different markets: dietary
supplements (nutraceuticals); food/beverage ingredients; and
pharmaceuticals.
In addition, Neptune Krill Oil, which appears to be the best
source of Omega-3s available today, has multiple blockbuster
applications in drug development, yet it avoids the classic pitfall
of a cash-burning biotech (running out of money) because Neptune is
already generating cash flow and earnings from the sale of their
nutraceutical Omega-3 product, Neptune Krill Oil (NKO), while the
subsidiary developing the cardiovascular drugs, Acasti Pharma, is
scheduled to start generating revenues from the sales of its
Medical Food and OTC products in the very near term.
A recent report on the company, their human trials with Krill
Oil as well as the cash flow and earnings generating core that
gives the stock more substance than most biotechs is now available
at:
http://biomedreports.com/2011041365978/neptune-technologies-and-bioresources-presents-significant-value-and-opportunity.html
Investors interested in accessing BioMedReports' complete
database of clinical trials and upcoming FDA decisions can go
to:
http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html
News developments and live healthcare sector updates are
available constantly via twitter at:
http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and
financial sector. BioMedReports is not paid or compensated to
report the news and developments of publicly traded companies in
the healthcare sector of the markets.
Full disclosures and information about the stocks are available
at BioMedReports.Com
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contacts Only: Mary Davila Assistant Editor
BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax:
+1 888 210 3556
New Tymbal Resources (TSXV:NTB)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
New Tymbal Resources (TSXV:NTB)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024